TransThera Sciences (Nanjing). Inc.
2617.HK
Hong Kong Stock Exchange10.45
HKD
+0.18
- -
TransThera Sciences (Nanjing). Inc.
2617.HK
(Hong Kong Stock Exchange)
Recent
price
10.45
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- TransThera Sciences (Nanjing), Inc. (2617.HK) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes small molecule therapies targeting oncology, inflammatory and cardiometabolic diseases. Founded in 2014 and headquartered in Nanjing, Jiangsu Province, China, the company operates a fully integrated in-house R&D platform with a pipeline encompassing one core registrational-stage product, Tinengotinib (TT-00420), a next-generation spectrum-selective pan-FGFR inhibitor in Phase III trials for FGFR-altered cholangiocarcinoma and other refractory solid tumors including hepatocellular carcinoma, breast cancer and biliary tract cancer; TT-00973, a selective AXL kinase inhibitor in clinical development for various cancers; TT-01488, a non-covalent BTK inhibitor for relapsed or refractory B-cell lymphoma and hematologic malignancies; TT-01688, an oral S1P1 modulator for inflammatory diseases; TT-00920, an oral PDE9 inhibitor for central nervous system and chronic heart failure indications; TT-01025, an oral irreversible VAP-1 inhibitor for NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. TransThera focuses on global markets with clinical trials conducted across the United States, Europe and China, serving patients with high unmet needs in tumor, immunity, cardiovascular and inflammatory segments. In June 2025, the company listed H shares on the Hong Kong Stock Exchange, raising approximately HK$201 million (US$25.6 million) to fund Phase III trials of Tinengotinib and general corporate purposes, with cornerstone investors including Jiangbei Pharmaceutical, Akeso and Pharmablock subscribing over 64% of the offering; in November 2025, TransThera entered a major collaboration with Neurocrine Biosciences, granting rights outside Greater China to its preclinical NLRP3 inhibitors (including TT-02332) for multiple diseases with an upfront payment plus milestones potentially totaling US$881.5 million.